TELA Bio is a commercial-stage medical device company that makes and sells soft-tissue reconstruction products, primarily for hernia repair and plastic/reconstructive surgery. TELA's core products — OviTex and OviTex PRS — are built on the same underlying technology: layers of minimally processed biological material derived from sheep forestomach, reinforced with interwoven polymer fibers in proprietary embroidered patterns. The products are roughly 95% biologic by mass, designed to combine the tissue-integration benefits of biologic matrices with the mechanical strength of synthetic mesh, at a lower price than leading biologic competitors. OviTex is used in hernia repair and abdominal wall reconstruction, available across open, laparoscopic, and robotic procedures. OviTex PRS serves plastic and reconstructive surgery, including breast reconstruction. TELA sells primarily through a direct U.S. sales force, with a smaller presence in Europe. Hospitals and surgery centers are the customers, with surgeons driving purchasing decisions. Revenue is generated on a per-unit basis, with pricing driven by product size and configuration. A key feature of TELA's cost structure is its supply agreement with Aroa Biosurgery, the exclusive manufacturer, which charges a fee equal to 27% of net sales — directly tying COGS to revenue. The other major cost driver is the direct sales force, which has historically run at roughly 75–85% of revenue. TELA is not yet profitable and is targeting profitability as revenue scales.